Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
Status:
Recruiting
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
This research study is studying immunotherapy in combination with radiation therapy as a
possible treatment for head & neck cancer that has worsened or spread to another organ or
part of your body.
The immunotherapy involved in this study is: MK-3475 (pembrolizumab or KEYTRUDA).